© 1993 by Oxford University Press
Journal of the National Cancer Institute, Vol. 85, No. 12, 965-970,
June 16, 1993
© 1993 Oxford University Press
p53 as an Independent Prognostic Marker in Lymph Node-Negative Breast Cancer Patients
Oncologia Sperimentale C, Istituto Nazionale per lo Studio e la Cura dei Tumori Milan, Italy
Direzione Generale, Istituto Nazionale per lo Studio e la Cura dei Tumori Milan, Italy
Istituto di Biometria, Università degli Studi Milan
Oncologia Sperimentale C, Istituto Nazionale per lo Studio e la Cura dei Tumori and Centro di Studio sulla Patologia Cellulare del CNR Milan
Correspondence to: Rosella Silvestrini, Ph.D., Oncologia Sperimentale C, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy.
BACKGROUND:: At present, most decisions concerning the use of adjuvant therapy in lymph node-negative breast cancer patients are made on the basis of traditional factors such as tumor size, nodal status, and histopathologic features. However, prognostic factors are being investigated that could identify high-risk groups and that could better address treatment efforts for those patients. Identification of more accurate prognostic markers, such as the expression of the mutant p53 protein encoded by the p53 (also known as TP53) tumor suppressor gene, that are reproducible, easily assessable, and independent in predicting clinical outcome would have a beneficial impact on cancer treatment decisions. Purpose: Our Purpose was to analyze the predictive relevance of mutant p53 protein expression on 6-year relapse-free and overall survival in node-negative breast cancer patients in relation to menopausal status, tumor size, cell kinetics, and estrogen receptor status. Methods: Expression of mutant p53 protein was detected by an immunohistochemical technique using a 1: 50 dilution of PAb1801 monoclonal antibody on paraffin-embedded tumor specimens obtained from 256 axillary lymph nodenegative breast cancer patients, with long-term follow-up (median, 72 months). The [3H]thymidine labeling index, a measure of cell kinetics, was evaluated on histologic sections after fresh tumor tissue was labeled with [3H]thymidine. Estrogen receptor status was determined by the dextran-coated charcoal absorption technique. Statistical comparisons were made for levels of p53 protein expression, [3H]thymidine labeling index, estrogen receptor status, tumor size, and menopausal status with respect to 6-year relapse-free survival and overall survival. Results: Overexpression of the p53 protein, defined as the presence of more than 5% positive cells, was detected in 113 (44%) of 256 tumors. Odds ratios (ORs) for multiple regression analysis of 6-year relapse-free survival were significantly higher for p53 (OR = 3.24; 95% confidence limits [CL] = 2.01–5.23) and [3H]thymidine labeling index (OR = 1.92; 95% CL = 1.19–3.12), both of which appeared to be the most relevant indicators of relapse, than for tumor size (OR = 1.49; 95% CL = 0.94–2.38) and estrogen receptor status (OR = 0.91; 95% CL = 0.55–1.51). Overexpression was found to be unrelated to menopausal status. Conclusions: Immunohistochemically detected p53 overexpression is an independent marker for shortened 6-year relapse-free and overall survival in node-negative patients with resectable breast cancers. Based on these findings, p53 overexpression should be used with other established prognostic factors, such as [3H]thymidine labeling index and estrogen receptor status, to further refine the prognostic assessment of node-negative breast cancer. [J Natl Cancer Inst 85: 965–1970, 1993]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  V Malamou-Mitsi, H Gogas, U Dafni, A Bourli, T Fillipidis, M Sotiropoulou, D Vlachodimitropoulos, S Papadopoulos, O Tzaida, G Kafiri, et al. Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy Ann. Onc., October 1, 2006; 17(10): 1504 - 1511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bottini, A. Berruti, A. Bersiga, M. P. Brizzi, G. Allevi, G. Bolsi, S. Aguggini, A. Brunelli, E. Betri, D. Generali, et al. Changes in Microvessel Density As Assessed by CD34 Antibodies after Primary Chemotherapy in Human Breast Cancer Clin. Cancer Res., June 1, 2002; 8(6): 1816 - 1821. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Van Poznak, L. Tan, K. S. Panageas, C. D. Arroyo, C. Hudis, L. Norton, and A. D. Seidman Assessment of Molecular Markers of Clinical Sensitivity to Single-Agent Taxane Therapy for Metastatic Breast Cancer J. Clin. Oncol., May 1, 2002; 20(9): 2319 - 2326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. K. Linderholm, T. Lindahl, L. Holmberg, S. Klaar, J. Lennerstrand, R. Henriksson, and J. Bergh The Expression of Vascular Endothelial Growth Factor Correlates with Mutant p53 and Poor Prognosis in Human Breast Cancer Cancer Res., March 1, 2001; 61(5): 2256 - 2260. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. Behrens, L. B. Travis, I. I. Wistuba, S. Davis, A. Maitra, E. A. Clarke, C. F. Lynch, B. Glimelius, T. Wiklund, R. Tarone, et al. Molecular Changes in Second Primary Lung and Breast Cancers after Therapy for Hodgkin's Disease Cancer Epidemiol. Biomarkers Prev., October 1, 2000; 9(10): 1027 - 1035. [Abstract] [Full Text]
|
|
|
|
|
|
D. Amadori, O. Nanni, M. Marangolo, P. Pacini, A. Ravaioli, A. Rossi, A. Gambi, G. Catalano, D. Perroni, E. Scarpi, et al. Disease-Free Survival Advantage of Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Patients With Node-Negative, Rapidly Proliferating Breast Cancer: A Randomized Multicenter Study J. Clin. Oncol., September 17, 2000; 18(17): 3125 - 3134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bottini, A. Berruti, A. Bersiga, M. P. Brizzi, A. Brunelli, G. Gorzegno, B. DiMarco, S. Aguggini, G. Bolsi, F. Cirillo, et al. p53 but not bcl-2 Immunostaining Is Predictive of Poor Clinical Complete Response to Primary Chemotherapy in Breast Cancer Patients Clin. Cancer Res., July 1, 2000; 6(7): 2751 - 2758. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. Perz and J. G. Kuhn Review : p53 in the pathogenesis, diagnosis, and treatment of cancer Journal of Oncology Pharmacy Practice, June 1, 1998; 4(2): 75 - 102. [Abstract] [PDF]
|
|
|
|
 |
|
 E. Benini, A. Costa, G. Abolafio, and R. Silvestrini p53 Expression in Human Carcinomas: Could Flow Cytometry Be an Alternative to Immunohistochemistry? J. Histochem. Cytochem., January 1, 1998; 46(1): 41 - 48. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. Robbins p53 and Breast Cancer International Journal of Surgical Pathology, October 1, 1996; 4(2): 93 - 110. [Abstract] [PDF]
|
|
|
|
 |
|
 S. S. Wachtel, G. Wachtel, L. P. Shulman, O. Phillips, B. Miller, and G. Photopulos Identification of p53 Mutations in Endometrial Adenocarcinoma by Polymerase Chain Reaction-Single-Strand Conformation Polymorphism Reproductive Sciences, July 1, 1994; 1(3): 234 - 237. [Abstract] [PDF]
|
|
|
|
 |
|
 C. C. Harris and M. Hollstein Clinical Implications of the p53 Tumor-Suppressor Gene N. Engl. J. Med., October 28, 1993; 329(18): 1318 - 1327. [Full Text]
|
|